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Abstract. MicroRNAs (miRNAs) are reported to be involved 
in the development of glioma. However, study on miRNAs in 
glioma is limited. The present study aimed to identify miRNAs 
which can act as potential novel prognostic markers for glioma 
and analyze its possible mechanism. We show that miR-1908 
correlates with shorter survival time of glioma patients via 
promoting cell proliferation, invasion, anti-apoptosis and 
regulating SPRY4/RAF1 axis. Analysis of GEO and TCGA 
database found that miR-1908 was significantly upregulated in 
glioma tissues, and strongly associated with shorter survival 
time of glioma patients. Further Gene Ontology (GO) and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis 
revealed that miR-1908 is mainly involved in regulating cell 
proliferation, invasion and apoptosis. To further confirm the 
above results, in vitro, glioma U251 cells were transfected 
with miR-1908 mimics or inhibitor, and upregulated miR-1908 
promoted U251 cell proliferation, and enhanced the ability 
of invasion by Transwell assay. In addition, upregulated 
miR-1908 also enhanced anti-apoptosis ability of U251 cells 
through decreasing pro-apoptosis protein Bax expression. 
Since miRNAs regulate numerous biological processes by 
targeting broad set of messenger RNAs, validated target 
genes of miR-1908 in glioma were analyzed by TargetScan 
and miRTarBase databases. Among them SPRY4 was signifi-
cantly decreased in glioma tissues and associated with short 
survival time, which was selected as the key target gene of 
miR-1908. Moreover, protein-protein interaction (PPI) showed 
that SPRY4 could interacted with pro-oncogene RAF1 and 
negatively correlated with RAF1 expression. Consistent with 
above analysis, in vitro, western blot analysis identified that 
miR-1908 upregulated significantly decreased SPRY4 expres-
sion and increased RAF1 expression. Hence, miR-1908 was 
correlated with poor prognosis of glioma via promoting cell 
proliferation, invasion, anti-apoptosis and regulating SPRF4/
RAF1 axis. Our results elucidated the tumor promoting role 
of miR-1908 and established miR-1908 as a potential novel 
prognostic marker for glioma.
Introduction
Glioma is one of the most common primary intracranial 
malignant tumors in adults (1), and survival time after diag-
nosis is approximately one year. The profuse infiltration of 
glioma cells into healthy tissue surrounding the main tumor 
mass is one of the major obstacles limiting the improvement 
of patient survival (2). The incidence and mortality rate of 
glioma still continues to increase (3). Although many genetic 
and epigenetic changes were found to be related to glioma, the 
pathogenesis remains poorly understood.
miRNAs are a class of small molecular non-coding regula-
tory RNAs, which act as oncogenes or tumor suppressors in 
a variety of tumors (4,5). Systematic and integrative analysis 
could detect key miRNAs that contribute to cancer develop-
ment (6). The abnormal expression of miRNAs involved in 
transcriptional regulation network leads to tumor initiation 
and progression. Its main mechanism includes one-to-many 
and many-to-one regulation between transcription factor 
to miRNA and miRNA to target gene, which increases the 
complexity of miRNA regulation, thus, affecting the biological 
behavior of the tumor (7). Hence, there is considerable interest 
in using deregulated miRNAs as prognosis prediction markers 
and understanding their molecular targets for cancer treatment.
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During glioma occurrence and progression, abnormal 
expression of miRNAs was found to exert important functions. 
miR-182, miR-199b and miR-203 were upregulated (8-10), 
while miR-451, miR-17 and miR-184 were downregulated in 
glioma tissues (11,12). These miRNAs were also reported to 
be involved in the development of glioma. However, miRNAs 
influencing glioma occurrence and progression is far from 
completely investigated, and no miRNA marker is used 
in clinic. Thus, there is still a growing need for developing 
prognostic markers and identifying therapeutic targets for 
improving the outcomes of glioma patients.
In the present study, we found that miR-1908 was signifi-
cantly upregulated in glioma tissues. High level of miR-1908 
was correlated with the shorter survival time of glioma, 
and promoted glioma cell proliferation and invasion and 
suppressed apoptosis. miR-1908 exerted these functions by 
regulating SPRY4/RAF1 axis and changing the expression 
of apoptosis related proteins Bcl-2/Bax and matrix metal-
lopoteinase-2 (MMP-2). These results help to elucidate the 
pathogenesis and predict prognosis of glioma.
Materials and methods
Bioinformatics analysis. To identify the expression of 
miRNAs in primary human glioma and normal cerebral tissue, 
data about miRNA expression level in glioma patients were 
obtained from Gene Expression Omnibus (GEO) database 
(https://www.ncbi.nlm.nih.gov/gds/). Clinical data such as 
overall survival (OS), disease-free survival (DFS), lymph node 
metastasis, TNM stage and miR-1908 expression level were 
extracted from the Cancer Genome Atlas (TCGA) database 
(https://cancergenome.nih.gov/). Target genes of miR-1908 
were analyzed by TargetScan (http://www.targetscan.org/) 
and miRTarBase database (experimentally validated miRNA-
target interactions database, http://mirtarbase.mbc.nctu.edu.
tw/). Enrichment analysis was performed by cBioPortal online 
database (http://www.cbioportal.org/). The pathological 
images and IHC data of glioma were downloaded from the 
Human Protein Atlas web portal (www.proteinatlas.org), the 
sum IOD was analyzed by Image-Pro Plus software (version 
6.0; Media Cybernetics, Inc., Rockville, MD, USA).
Gene ontology and KEGG pathway analyses. To explore 
the functional annotation enrichment of the target genes of 
miR-1908 in glioma, GO and KEGG analyses were conducted 
using the Database for Annotation, Visualization and 
Integrated Discovery (DAVID) online analysis tool (https://
david.ncifcrf.gov/). The database provides a comprehensive set 
of functional annotation tools for investigators to understand 
biological meaning behind large list of genes, especially for 
identifying enriched biological themes.
Cell culture and miRNA transfection. Human glioma cell line 
U251 was purchased from the Cell Resource Center of Beijing 
Xiehe (Beijing, China) and cultivated in an incubator at 37˚C with 
5% CO2. U251 cells were maintained in high-glucose Dulbecco's 
modified Eagle's medium (DMEM; Gibco, Waltham, MA, USA) 
supplemented with 10% fetal bovine serum (FBS; HyClone 
Laboratories, Inc., Logan, UT, USA) as well as penicillin (100 U/
ml; Thermo Fisher Scientific, Waltham, MA, USA).
miR-1908 mimics, miR-1908 inhibitor and their nega-
tive control (NC) sequences were designed and synthesized 
by Suzhou GenePharma Co., Ltd. (Shanghai, China). 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was 
used for miRNA oligo transfection according to the manufac-
turer's protocol. After 48 h of transfection, cells were used for 
the following experiments.
RNA isolation and quantitative real-time PCR assay 
(qRT-PCR). Total RNA was extracted from U251 cells trans-
fected with miR-1908 mimics or inhibitor using the TRIzol 
reagent (Invitrogen) according to the manufacturer's protocol. 
RNA quantity and purity were assessed using NanoDrop 
ND-1000 (Thermo Fisher Scientific). Total RNA was reverse-
transcribed to cDNA, and the first-strand cDNA was used as 
a template for real-time PCR (13). Reactions of qRT-PCR was 
done on the ABI Prism 7500 (Applied Biosystems, Foster City, 
CA, USA) using the commercially available gene expression 
assay for miR-1908, SPRY4 and RAF1. All reactions were run 
in triplicate. Relative gene expression was quantified using U6 
or GAPDH as an internal control.
CCK-8 assay. Cells transfected with miR-1908 mimics or 
inhibitor sequence were plated at a density of 5x103 cells/well 
onto 96-well plates at 37˚C in an incubator with 5% CO2. Cell 
proliferation was then assessed every 24 h using Cell Counting 
kit-8 (CCK-8; Sigma Aldrich St. Louis, MO, USA) according 
to standard protocol. For each sample at each time-point, six 
wells were analyzed. The experiment was repeated three times.
Cell invasion. Cell invasion abilities were determined in 
Transwell assays. Briefly, to determine the invasion potential, 
DMEM containing 10% FBS was added to the lower cham-
bers, and 1x105 cells suspended in 200 µl serum-free medium 
were added to the upper chambers with Matrigel matrix gel 
and cultured for 24 h. Finally, the cells that traversed the 
membrane were stained with crystal violet and counted.
Gelatin zymography assay. Activities of MMP-2 and MMP-9 
were assessed by gelatin zymography assay. U251 cells were 
cultured for 24 h after transfecting the miR-1908 mimics or 
inhibitor. At the end of incubation, 40 µl of culture superna-
tant was mixed with sample buffer and resolved on a 10% 
SDS-PAGE under non-reducing conditions. The gel was 
co-polymerized containing 0.5 mg/ml of gelatin (Sigma-
Aldrich). Gel was washed twice for 30 min with renaturation 
buffer (2.5% Triton X-100) at room temperature before incuba-
tion in the incubation buffer (50 mM Tris-HCl pH 7.5, 200 mM 
NaCl, 10 mM CaCl2, 1 µM ZnCl2) at 37˚C for 36 h. Thereafter, 
gel was stained for 2 h in 0.25% Coomassie brilliant blue R-250 
and then de-stained. White bands were observed against a blue 
background after de-staining, indicating gelatinolytic activi-
ties of MMP-2 and MMP-9.
Western blotting. Cells were collected and lysed in lysis buffer 
(Beijing CoWin Biotech Co., Ltd., Beijing, China) in the pres-
ence of protease inhibitors for 30 min to extract total protein 
from cells transfected with miR-1908 mimics or inhibitor, and 
protein levels were quantified using bicinchoninic acid assays 
(Beijing CoWin Biotech). Subsequently, 30 µg protein from 
ONCOLOGY REPORTS  38:  2717-2726,  2017 2719
each sample was loaded onto 10% sodium dodecyl sulfate (SDS) 
polyacrylamide gels and subjected to SDS-polyacrylamide gel 
electrophoresis (PAGE; Beijing CoWin Biotech). Protein was 
then transferred to nitrocellulose membranes (Sigma-Aldrich), 
which were then blocked with bovine serum albumin buffer 
(BSA; Invitrogen) for 1 h. Membranes were then incubated 
with primary antibodies targeting SPRY4 (1:1,000 dilution, 
cat. no. ab59785; Abcam), RAF1 (1:1,000 dilution, cat. no. 
ab154754; Abcam), Bax (1:2,000 dilution, cat. no. ab182733; 
Abcam), Bcl-2 (1:1,000 dilution, cat. no. ab194583; Abcam) 
or GAPDH (1:5,000 dilution, cat. no. ab70699; Abcam) 
overnight at 4˚C, followed by incubation with goat anti-rabbit 
horseradish peroxidase (HRP)-conjugated secondary antibody 
(1:3,000 dilution, cat. no. CW0103; Beijing CoWin Biotech) for 
1 h at room temperature. Detection was facilitated using an 
enhanced chemiluminescence kit and images were analyzed 
using ImageJ software (version 1.62; National Institutes of 
Health, Bethesda, MD, USA).
Annexin V-FITC/PI apoptosis detection. Annexin V-FITC/PI 
(BD Biosciences, Bedford, MA, USA) was used to detect cell 
apoptosis rate. In brief, U251 cells transfected with miR-1908 
mimics or inhibitor were washed twice with cold phosphate-
buffered saline (PBS), and cells were added in 400 µl binding 
buffer (provided by the manufacturer) at a concentration of 
1x106 cells/ml. Annexin V-FITC (5 µl) and PI (5 µl) were then 
added, and the cells were analyzed with a flow cytometer (BD 
Accuri C6; BD Biosciences) within 1 h (13).
Protein-protein interaction (PPI) network construction. 
Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING; Search Tool for the Retrieval of Interacting Genes, 
http://string-db.org/) is a database of known and predicted 
protein interactions that may aid in the comprehensive 
description of cellular mechanisms and functions. The PPI 
network of the selected target genes of miR-1908 in glioma 
was constructed using the STRING database.
Statistical analysis. Statistical analyses were performed using 
the SPSS 21.0 (SPSS, Inc., Chicago, IL, USA) and GraphPad 
Prism (GraphPad Software, Inc., San Diego, CA, USA). GEO 
microarray data and TCGA data were analyzed by paired 
sample t-test. The log-rank test for the generated Kaplan-
Meier (K-M) curve was conducted to evaluate the association 
between the expression level of miR-1908 and the survival 
rate. OS was defined as the time between the first surgery for 
primary glioma and death for any reason. DFS was defined 
as the time between the first surgical resection and disease 
recurrence. Growth curves were analyzed using a repeated 
measures ANOVA followed by Bonferroni post hoc analysis. 
Cell invasion data, apoptosis data and IHC data were analyzed 
by independent samples t-test. The correlation of target genes 
of miR-1908 expression level was analyzed by the Pearson 
correlation analysis. P<0.05 was considered to indicate a 
statistically significant difference.
Results
Increased expression of miR-1908 in glioma and its associa-
tion with shorter survival time in the patients. We used GEO 
microarray and TCGA miRNA dataset to screen miRNAs 
which related to glioma occurrence and development. Three 
pairs of glioma tissues and adjacent normal cerebral tissues 
were compared by miRNA microarray, 53 differentially 
expressed miRNAs (P<0.05; FC>1 and FC<-1) were identified. 
Of which, miR-1908 was one of rarely reported miRNAs in 
glioma and attracted our interest (Fig. 1A and Table I).
To further validate the abnormal regulated expression level 
of miR-1908, we compared the expression level of miR-1908 in 
glioma tissue and normal tissue by GEO database. Consistent 
with previous reports, miR-1908 was significantly upregulated 
in tumor tissue specimens (n=89) compared with matched 
normal controls (n=32) (Fig. 1B; P=0.0343). To further deter-
mine the predictive value of miR-1908 expression level as 
prognostic marker, 206 glioma patients from TCGA database 
Table I. The main dysregulated miRNAs in glioma tissue.
No. Name log2 fold change Average expression P-value
  1 hsa-miR-129-1-3p -1.182734902 1.36366824 0.026579
  2 hsa-miR-6749-5p 1.063017222 6.664388833 0.027495
  3 hsa-miR-6789-5p 1.538438528 6.707455986 0.027804
  4 hsa-mir-6800 1.041350944 8.824345889 0.027867
  5 hsa-miR-4310 1.023917706 2.157122464 0.028345
  6 hsa-mir-628 -1.084536185 1.309829702 0.029722
  7 hsa-miR-1908-5p 1.031185667 8.369524444 0.030411
  8 hsa-miR-7977 -1.52912775 7.489592208 0.033013
  9 hsa-miR-1238-3p 1.018972278 1.632209472 0.033941
10 hsa-miR-3162-5p 1.320415407 5.361444565 0.033947
11 hsa-mir-5095 1.224927278 4.761240056 0.036548
12 hsa-miR-6503-3p 1.830256801 2.51717765 0.03752
13 hsa-miR-4767 1.9436247 2.648728206 0.037793
14 hsa-miR-8089 1.274433444 4.688330611 0.039185
15 hsa-miR-6724-5p 1.074298778 9.620908778 0.043217
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were divided into miR-1908 high expression and miR-1908 low 
expression groups according to median miR-1908 expression 
level. K-M curve showed that miR-1908 high expression group 
had shorter OS and DFS time than miR-1908 low expression 
group in terms of survival duration (Fig. 1C and D; P<0.0001 
and P=0.0028, respectively), particularly in overall survival. 
The result suggests that upregulated miR-1908 may be a novel 
prognostic marker for glioma patients.
miR-1908 is involved in multiple types of cancer-related path-
ways. In order to understand the function and role of miR-1908 
in tumor progression, GO and KEGG pathway analysis 
were performed. We noted that these genes were especially 
enriched in functions of regulating cell proliferation, invasion 
and apoptosis (Fig. 2A). miRNAs were reported to promote 
cancer occurrence and progression through activating related 
signaling pathways. To better understand underlying molecular 
mechanisms in which miR-1908 plays roles, we investigated 
miR-1908 relevant KEGG pathways. Results revealed that 
miR-1908 was involved in 54 significant KEGG pathways, 
the main signaling pathways are shown in Fig. 2B. These 
pathways mainly included multiple types of cancer-related 
signaling pathways, especially the Jak-STAT, MAPK and Ras 
signaling pathways.
miR-1908 promotes cell proliferation and invasion of 
glioma. In order to demonstrate the effect of miR-1908 on 
glioma malignant phenotype, we performed cell prolifera-
tion and invasion assays. qRT-PCR results reveal that relative 
miR-1908 level was upregulated in U251 cells transfected 
Figure 1. Expression level of miR-1908 in glioma tissues is upregulated. (A) Screening of differentially expressed genes in glioma based on GEO database. 
(B) The miR-1908 level was upregulated in glioma tissues (n=89) compared with adjacent normal tissues (n=32) by GEO analysis. (C) K-M curve for overall 
survival (OS) of patients with high (n=103) and low (n=103) miR-1908 expression level. Results revealed that high miR-1908 expression level was correlated 
with shorter OS for glioma patients. (D) Patients with high miR-1908 expression (n=103) had shorter disease-free survival (DFS) time than those with low 
miR-1908 expression (n=103).
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with miR-1908 mimics (Fig. 3A; P=0.0239), and miR-1908 
level was downregulated after miR-1908 inhibitor transfec-
tion (Fig. 3B; P=0.0210). The ability of miR-1908 to modulate 
the proliferation of U251 cells was analyzed using a CCK-8 
assay. The results indicated that downregulated miR-1908 
could inhibit cell proliferation in 72 and 96 h (Fig. 3C; 
P=0.0285 and P=0.0152, respectively), while upregulated 
miR-1908 significantly enhanced the ability of cell prolifera-
tion (Fig. 3D; P=0.0254 and P=0.0196, respectively). Similarly, 
upregulated miR-1908 also significantly promoted cell inva-
sion compared with control group through Transwell assay, on 
the contrary, downregulated miR-1908 in U251 cells inhibited 
invasion (Fig. 3E and F; P=0.026 and P=0.030, respectively).
Previous studies have shown that proteolysis is a necessary 
part of the invasion process (14), and that increased expression 
of several members of the MMP family are correlated with 
high-grade gliomas, especially MMP-2/9 (15). We therefore 
detected the activity of MMP-2/9 by using gelatin zymography 
assay. The results revealed that upregulated miR-1908 
expression significantly enhanced the activity of MMP-2, but 
there was no significant difference in MMP-9 activity between 
miR-1908 mimics group and control group (Fig. 3G and H).
miR-1908 inhibits cell apoptosis via regulating Bax/Bcl-2 
expression. The processes of apoptosis, which induce 
degradation of proteins and organelles or cell death upon cellular 
stress, are crucial in the pathophysiology of various tumors. In 
order to observe the effect of miR-1908 overexpression on cell 
apoptosis, miR-1908 mimics or inhibitor were transfected into 
U251 cells, and apoptosis rate and the expression of apoptosis-
associated protein Bax/Bcl-2 were detected by flow cytometry 
and western blot analysis, respectively. Representative results of 
flow cytometric analysis are shown in Fig. 4A and C. In general, 
the rates of cell death were low (<5%). Apoptosis rate was not 
statistically different in cells transfected with miR-1908 mimics 
Figure 2. miR-1908 is involved in multiple types of cancer-related pathways. 
(A) GO analysis of the miR-1908 according to biological process, molecular 
function and cellular component. (B) miR-1908 was involved in 10 signifi-
cant signaling pathways. 
Table II. The main target genes of miR-1908.
  Cumulative Total
 Gene weighted context Aggregate
No. name context score score PCT
  1 PRSS22 -1.51 -1.51 N/A
  2 TOR4A -1.02 -1.02 N/A
  3 ZNF385A -0.9 -0.9 N/A
  4 DPF1 -0.9 -0.9 N/A
  5 SRCIN1 -0.8 -0.8 N/A
  6 SCAMP4 -0.79 -0.79 N/A
  7 RAB11B -0.75 -0.97 N/A
  8 GNAI2 -0.74 -0.74 N/A
  9 NRGN -0.7 -0.7 N/A
10 NKX2-5 -0.7 -0.78 N/A
11 H2AFX -0.62 -0.62 N/A
12 POU3F1 -0.54 -0.54 N/A
13 BARHL1 -0.53 -0.53 N/A
14 FAM83H -0.49 -0.49 N/A
15 SLC11A1 -0.49 -0.49 N/A
16 GRB2 -0.45 -0.45 N/A
17 CALR -0.43 -0.43 N/A
18 PRX -0.42 -0.42 N/A
19 POFUT2 -0.41 -0.41 N/A
20 TACC3 -0.41 -0.41 N/A
21 CASZ1 -0.41 -0.41 N/A
22 GPR20 -0.4 -0.48 N/A
23 SIGLEC12 -0.4 -0.4 N/A
24 MYADM -0.38 -0.45 N/A
25 SPRY4 -0.38 -0.47 N/A
26 SYNGR1 -0.37 -0.37 N/A
27 MARVELD1 -0.36 -0.36 N/A
28 PHF15 -0.36 -0.53 N/A
29 APOE -0.33 -0.33 N/A
30 NACC1 -0.33 -0.36 N/A
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and negative control sequences (Fig. 4B; P=0.083). However, 
U251 cells transfected with miR-1908 inhibitor had significantly 
higher rate of apoptosis when compared with cells transfected 
with negative control sequences (Fig. 4D; P=0.027). Furthermore, 
transfection of miR-1908 inhibitor caused an increase in the 
expression of Bax, a pro-apoptotic protein, but a marked decrease 
in the expression of Bcl-2, an anti-apoptotic protein. In contrast, 
transfection of miR-1908 mimics downregulated the expression 
level of Bax. These data supported that miR-1908 enhances the 
ability of cell anti-apoptosis via regulating Bax/Bcl-2 expression.
SPRY4 is a key target gene of miR-1908 in glioma. miRNAs 
exert important functions in various biological processes 
via directly suppressing the expression of their target genes. 
According to integration analysis from TargetScan and 
miRTarBase database, 96 verified target genes (5) of miR-1908 
were identified (Fig. 5A and Table II). Of which, SPRY4 was 
significantly downregulated in glioma tissue (n=11) compared 
with normal tissue (n=2) (Fig. 5B and C; P=0.0054). Moreover, 
patients with SPRY4 alteration had lower OS and DFS 
compared with patients without alteration (Fig. 5D and E; 
Figure 3. miR-1908 promotes glioma cell proliferation and invasion. (A and B) The expression of miR-1908 in U251 cell were affected by transfection of 
miR-1908 mimics or inhibitor. (C) Downregulated miR-1908 level inhibited the proliferation of U251 cells. (D) miR-1908 significantly promoted the pro-
liferation of U251 cells by >50% at all time-points following 72 h of incubation. (E and F) Upregulated miR-1908 enhanced invasion ability of glioma cells. 
(G and H) miR-1908 mimics enhanced the activity of MMP-2, while miR-1908 inhibitor reduced its activity.
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Figure 4. miR-1908 enhances the ability of glioma cell anti-apoptosis via regulating Bcl-2/Bax expression. (A-D) Double staining with Annexin V-FITC and 
PI was used to assess apoptosis in U251 cells transfected with miR-1908 mimics or inhibitor, and miR-1908 inhibitor markedly increased cell apoptosis rate. 
(E) Western blot analysis was performed to determine Bcl-2 and Bax protein expression in U251 cells transfected with miR-1908 mimics or inhibitor, and Bax 
was increased following transfection with miR-1908 inhibitor, but a marked decrease in the expression of Bcl-2. In contrast, transfection of miR-1908 mimics 
downregulated the expression level of Bax. 
Figure 5. SPRY4 is a key target gene of miR-1908. (A) Target genes of miR-1908 were identified by TargetScan and miRTarBase database. (B and C) The 
Human Protein Atlas database results revealed that the expression level of SPRY4 was downregulated in glioma compared with normal tissues. (D) K-M curve 
for OS of patients with (n=33) and without (n=480) alteration. (E) Patients with SPRY4 alteration (n=27) had shorter DFS than without alteration (n=450).
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P<0.0001). Hence, SPRY4 may be a key and specific target 
gene of miR-1908 in glioma.
SPRY4/RAF1 axis is regulated by miR-1908 in glioma. PPI 
analysis revealed that SPRY4 can interact with multiple 
proteins, included SPRY2, SPRY1, SPRY3, HRAS, CBL, 
RASA1, RAF1, FGF8 and PTPRB (Fig. 6A and B). Above 
all, RAF1 is a well-known pro-oncogene in multiple types of 
tumors (16). The abnormal upregulation of RAF1 protein plays 
an important role in the malignant transformation of tumor. 
In glioma tissues (n=11), RAF1 protein expression levels was 
significantly upregulated (Fig. 6C and D; P=0.0135) compared 
with normal tissues (n=3). To further verify the relationship 
between SPRY4 and RAF1, correlation analyses between 
expression levels of SPRY4 and RAF1 were performed in 
glioma tissues. The results showed that the expression level of 
SPRY4 was negatively correlated with the expression level of 
RAF1 (Fig. 6E; Pearson=-0.1682, P=0.0336). In addition, gene 
co-expression analysis revealed that RAF1 was significantly 
co-expressed with SPRY4 (Table III). To further validate 
whether miR-1908 could promote the expression of RAF1 via 
targeting SPRY4, miR-1908 mimics were transfected into U251 
cells. qRT-PCR assay showed that SPRY4 mRNA level was 
downregulated in these cells, on the contrary, RAF1 mRNA 
level was significantly upregulated (Fig. 6F and G; P=0.0384 
and P=0.0211, respectively). Similarly, compared with negative 
group, the expression level of SPRY4 in U251 cells transfected 
with miR-1908 mimics was significantly downregulated and 
Figure 6. miR-1908 upregulates the expression level of RAF1 through targeting SPRY4. (A and B) PPI analysis of interaction genes with SPRY4, and interac-
tion with pro-oncogene RAF1. (C and D) The expression level of RAF1 was upregulated in glioma tissue compared with normal tissue. (E) The expression 
level of SPRY4 was negatively correlated with RAF1 in glioma patients from TCGA KIRC database. (F and G) miR-1908 mimics were transfected into U251 
cells, the relative mRNA level of SPRY4 and RAF1 were detected by qRT-PCR. (H) Upregulated miR-1908 promoted RAF1 expression via decreasing the 
expression of SPRY4.
ONCOLOGY REPORTS  38:  2717-2726,  2017 2725
the expression level of RAF1 was increased (Fig. 6H). These 
data suggested that miR-1908 contributed to tumor progres-
sion through modulation of SPRY4/RAF1 axis in glioma.
Discussion
In the present study, integrative analysis of GEO and TCGA 
data suggested that the expression level of miR-1908 was 
significantly upregulated in glioma tissues and was associated 
with shorter survival time of glioma patients. Furthermore, we 
verified that miR-1908 could promote glioma cell prolifera-
tion, invasion, anti-apoptosis and regulate SPRY4/RAF1 axis. 
These results elucidated that miR-1908 is a novel prognosis 
marker via promoting malignant phenotype and modulating 
SPRY4/RAF1 axis. To the best of our knowledge, this is the 
first report showing prognostic value of miR-1908 for glioma 
patients.
A previous work demonstrated that miR-1908 was 
aberrantly expressed in several types of tumors, including 
osteosarcoma (17), lung (18) and liver cancer (19). miR-1908 is 
strongly associated with cell proliferation and migration (17), 
and poor prognosis of osteosarcoma patients (20). miR-1908 
exerts these effects via regulating many signaling pathways 
of tumor formation. For example, overexpressed miR-1908 
clusters downregulate the MARK1 signaling pathway to alter 
cell proliferation and differentiation in hepatoma cells, and 
serves as a biomarker for poor prognosis in osteosarcoma (20). 
miRNA-1908 functions as an oncogene in glioblastoma 
by repressing the PTEN signaling pathway (21). Notably, 
previous bioinformatics analysis also found that miR-1908 
may contribute to glioma progression and be correlated with 
survival rate (22), but lacks sufficient experimental bases. 
In this study, we not only showed that miR-1908 acts as a 
novel prognostic marker for glioma, but also explored its 
possible mechanisms. Clinical data showed that high expres-
sion of miR-1908 was correlated with shorter OS and DFS. 
Upregulation of miR-1908 in vitro promoted glioma cell 
proliferation and invasion, and suppressed its apoptosis. These 
data indicated that miR-1908 contributes to poor prognosis of 
glioma patients via promoting glioma cell malignant behavior.
miRNAs play their roles via suppressing the expression of 
target mRNAs. Actually, the biological interactions between 
miRNAs and their targets are very complex in vivo. One 
miRNA may target multiple genes and target genes are tissue 
specific (23,24). On the basis of known target gene database, 
we further combined TargetScan and miRTarBase datasets 
and used cBioPortal online analysis tool to find the tissue 
specific and key target genes of miR-1908 in glioma. Among 
them, SPRY4, a tumor suppressor, was downregulated in 
glioma patients and patients with SPRY4 alteration had shorter 
OS and DFS. Hence, SPRY4 was identified as a key target gene 
of miR-1908.
Our further analysis revealed that mainly ten proteins 
in glioma could interact and form the complex with SPRY4. 
Among these ten interacting proteins, RAF1 is a well-known 
pro-oncogene (25). In glioma tissue, SPRY4 expression level 
was significantly downregulated, but RAF1 expression level 
was significantly upregulated. The relationship between 
SPRY4 and RAF1 were further verified by correlation analysis 
of expression levels in tissues and in vitro. miR-1908 could 
suppress the expression of SPRY4 and upregulate RAF1 
expression. Since proto-oncogene RAF1 serves as part of 
the mitogen-activated protein kinases/extracellular signal-
regulated kinase signal transduction pathway and regulates 
cell migration, apoptosis and differentiation (26), we speculate 
that miR-1908 may promote glioma progression through regu-
lating SPRY4/RAF1 axis. Further experiments are necessary 
to verify our hypothesis.
In conclusion, miR-1908 is potentially a novel prognostic 
biomarker for glioma via promoting glioma cell proliferation, 
invasion, anti-apoptosis and regulating SPRY4/RAF1 axis. 
This study provides a novel prognostic marker and a new treat-
ment direction for glioma.
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